MBrace Therapeutics Appoints Steve Alley as Chief Scientific Officer
MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the appointment of Steve Alley, Ph.D., as chief scientific officer.
- MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the appointment of Steve Alley, Ph.D., as chief scientific officer.
- Dr. Alley joins MBrace with over 20 years of experience at Seagen, a world-leader in ADCs that was acquired by Pfizer in 2023.
- “We are thrilled to welcome Dr. Alley to the MBrace team.
- Dr. Alley has exceptional expertise in ADC development, and his vision will undoubtedly help propel the progress for our discovery and clinical programs,” said Isan Chen, M.D., president and chief executive officer at MBrace Therapeutics.